AQUA BIO TECHNOLOGY ASA: PUBLICATION OF PROSPECTUS – LISTING OF NEW SHARES – START OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the
"Company" or "ABT") published on 12 February 2019 regarding the Company's
resolution to complete a repair issue (the "Subsequent Offering") of up to
220,500 new shares (the "Offer Shares") and warrants (the "Warrants") in the
Company. The Subsequent Offering was conditioned upon approval and publication
of a prospectus prepared by the Company (the "Prospectus").

The Financial Supervisory Authority of Norway has on 13 February 2019 approved
the Prospectus in connection with the listing of the new shares and warrants
issued in the private placement completed by the Company on 4 December 2018 (the
"Private Placement") and the offering and listing of Offer Shares and Warrants
in the Subsequent Offering.

The shares issued in the Private Placement, currently registered on a separate
ISIN, will as a consequence be transferred to the ordinary ISIN of the Company
and become tradable on Oslo Axess as of today.

The subscription period in the Subsequent Offering commences on 14 February
2019 at 09.00 hours and expires on 28 February 2019 at 16.30 hours. Further
information about the Subsequent Offering is available in the Prospectus.

The Prospectus is available at the website of the Company,
www.aquabiotechnology.com.

For further information, please call Arvid Lindberg, Head of sales and
marketing, telephone +47 9824 5410 or arvid@aquabiotech.no.

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on the Axess market of the
Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.